Aquestive Therapeutics

AQST77

High Growth

$4.50arrow_drop_down4.32%-$0.20

High Growth

Penny Stock

AQST77

$4.50

arrow_drop_down4.32%-$0.20

High Growth

Penny Stock

Performance History

Key Stats
Open	$4.81
Prev. Close	$4.82
EPS	-0.45
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$434.91M
PE Ratio	-

	LOW	HIGH
Day Range	4.77	4.89
52 Week Range	1.29	6.23

Ratios







EPS	-0.45

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Aquestive Therapeutics (AQST)

Aquestive Therapeutics Inc (AQST) is a pharmaceutical company specializing in the development of innovative therapies to treat various medical conditions. The company has a strong focus on oral film technology, which allows for the delivery of drugs through the buccal mucosa. This technology offers several advantages over traditional drug delivery methods, including improved bioavailability and convenience for patients. Aquestive Therapeutics has successfully developed and commercialized several products using this technology, including Suboxone and Sympazan.

One of the key factors driving the success of Aquestive Therapeutics is its commitment to research and development. The company has a robust pipeline of potential new therapies, with several candidates in various stages of clinical development. This includes treatments for central nervous system disorders, allergies, and other medical conditions. Aquestive Therapeutics has also formed strategic partnerships with other pharmaceutical companies to further strengthen its product portfolio.

Websitecall_made

Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
CEO: Mr. Daniel Barber
Headquarters: Warren
Employees: 130
Exchange: NASDAQ

Keep an eye on Aquestive Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Aquestive Therapeutics 's (AQST) price per share?

The current price per share for Aquestive Therapeutics (AQST) is $4.5. The stock has seen a price change of -$0.21 recently, indicating a -4.33% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Aquestive Therapeutics (AQST)?

For Aquestive Therapeutics (AQST), the 52-week high is $6.23, which is 38.29% from the current price. The 52-week low is $1.29, the current price is 249.22% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Aquestive Therapeutics (AQST) a growth stock?

Aquestive Therapeutics (AQST) has shown an average price growth of -7.23% over the past three years. It has received a score of 89 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Aquestive Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Aquestive Therapeutics (AQST) stock price performance year to date (YTD)?

As of the latest data, Aquestive Therapeutics (AQST) has a year-to-date price change of 124.13%. Over the past month, the stock has experienced a price change of -8.99%. Over the last three months, the change has been 4.04%. Over the past six months, the figure is 41.22%. Looking at a longer horizon, the five-year price change stands at -22.06%.

help

Is Aquestive Therapeutics (AQST) a profitable company?

Aquestive Therapeutics (AQST) has a net income of -$7.87M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 58.82% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -61.22% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $50.58M, with a revenue growth rate of 6.09%, providing insight into the company's sales performance and growth. The gross profit is $29.75M. Operating income is noted at -$15.1M. Furthermore, the EBITDA is $2.56M.

help

What is the market capitalization of Aquestive Therapeutics (AQST)?

Aquestive Therapeutics (AQST) has a market capitalization of $415.77M. The average daily trading volume is 4.59, indicating the stock's liquidity and investor engagement.